Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 15;15(1):229.
doi: 10.1007/s12672-024-01090-1.

The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma

Long-Ying Zhu  1   2 , Qi-Lei Hu  2 , Liang Zhang  2 , Zuo-Jie Li  3
Affiliations
Review

The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma

Long-Ying Zhu et al. Discov Oncol. .

Abstract

Multiple myeloma (MM) denotes a cancerous growth characterized by abnormal proliferation of plasma cells. Growing evidence suggests that the complexity in addressing MM lies in the presence of minimal residual disease (MRD) within the body. MRD assessment is becoming increasingly important for risk assessment in patients with MM. Similarly, the levels of serum free protein light chain and their ratio play a crucial role in assessing the disease burden and changes in MM. In this paper, we review and explore the utilization of MRD and serum free light chain ratio in the treatment of MM, delving into their respective characteristics, advantages, disadvantages, and their interrelation.

Keywords: Duration of Response (DOR); Minimal residual disease (MRD); Multiple myeloma (MM); Serum free light chain ratio (sFLCR); Stringent complete response (sCR).

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interest.

Similar articles

See all similar articles

References

    1. Lonial S, Durie B, Palumbo A, San-Miguel J. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30(3):526–535. doi: 10.1038/leu.2015.223. - DOI - PMC - PubMed
    1. Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Phys. 2017;95(6):373–383. - PubMed
    1. Kang L, Zhang J, Li M, Xu N, Qi W, Tan J, et al. Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma. Biomark Res. 2020;13(8):14. doi: 10.1186/s40364-020-00192-6. - DOI - PMC - PubMed
    1. Rawstron AC, Paiva B, Stetler-Stevenson M. Assessment of minimal residual disease in myeloma and the need for a consensus approach. Cytometry B Clin Cytom. 2016;90(1):21–25. doi: 10.1002/cyto.b.21272. - DOI - PMC - PubMed
    1. Bai Y, Orfao A, Chim CS. Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol. 2018;181(1):11–26. doi: 10.1111/bjh.15075. - DOI - PubMed

LinkOut - more resources